• TPQL4- A TIME SERIES AND PANEL DATA APPROACH TO CROSS-TRANSLATE DESCRIPTIVE HEALTH STATUS TO HEALTH PREFERENCE IN PATIENTS WITH CHRONIC DISEASES

    May 1, 1999, 00:00

  • PPO2- THE DEVELOPMENT OF A PRACTICAL PROVIDER PROFILING REPORT

    May 1, 1999, 00:00

  • PCVD5- DELPHI PANEL SURVEY ON CURRENT HYPERTENSION TREATMENT PATTERNS

    May 1, 1999, 00:00

  • RD4- RELATIONSHIP AMONG DISEASE-SPECIFIC QUALITY OF LIFE AND CLINICAL CONSEQUENCES OF ASTHMA

    May 1, 1999, 00:00

  • PNP3- RACIAL AND GENDER DIFFERENCES IN ACCESS TO A NEW DRUG THERAPY

    May 1, 1999, 00:00

  • PID17- DETERMINATION OF THE COST-EFFECTIVENESS OF A TUBERCULOSIS PREVENTION PROGRAM ALONG THE US/ MEXICO BORDER USING MARKOV PROCESS MODELING WITHIN A PREVENTION EFFECTIVENESS FRAMEWORK

    May 1, 1999, 00:00

  • PKU1- A METHOD FOR COMPARING DISPARATE OUTCOME MEASURES IN OVERACTIVE BLADDER CLINICAL TRIALS

    May 1, 1999, 00:00

  • PCD7- INITIAL, MAINTENANCE, AND TERMINAL CARE COSTS OF BREAST CANCER TREATMENT

    May 1, 1999, 00:00

  • PNP7- SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) UTILIZATION PATTERNS IN PATIENTS WITH OR WITHOUT A DEPRESSION DIAGNOSIS

    May 1, 1999, 00:00

  • TPDM7- COST OF ISCHEMIC STROKE TREATMENT BY FUNCTIONAL STATUS- A MODEL COMPARING CITICOLINE TO STANDARD CARE

    May 1, 1999, 00:00

  • PG15- FACTORS INFLUENCING THE DURATION OF GI MEDICATION TREATMENT ASSOCIATED WITH NSAID-INDUCED GASTROPATHY

    May 1, 1999, 00:00

  • PCP8- ASSESSMENT OF SURGICAL ANESTHESIA AND POSTOPERATIVE ANALGESIA USING A PAIN VISUAL ANALOG SCALE

    May 1, 1999, 00:00

  • TPCP4- DISCRETE CHOICE MODELING ON PATIENT PERCEIVED COMPLIANCE- ANALYSIS OF PATIENTS HEALTH BELIEF PERSPECTIVE

    May 1, 1999, 00:00

  • PG17- RATE OF GI DISTRESS AMONG PATIENTS TREATED WITH CELECOXIB, PLACEBO, OR NSAIDs USING THREE DIFFERENT STATISTICAL METHODS

    May 1, 1999, 00:00

  • DP2- THE RELATIONSHIP BETWEEN PAYER TYPE AND HOSPITALIZATION RATES FOR ASTHMATICS SUBSEQUENT TO AN EMERGENCY ROOM VISIT

    May 1, 1999, 00:00

  • PID7- COST-EFFECTIVE ANALYSIS OF ORAL ONYCHOMYCOSIS THERAPIES USING IDAHO MEDICAID CLAIMS DATA

    May 1, 1999, 00:00

  • PCVD4- AN ECONOMIC MODEL OF HYPERTENSION IN ONTARIO

    May 1, 1999, 00:00

  • WDM1- CURRENT COMPUTER SOFTWARE AND HARDWARE OPTIONS IN PHARMACOECONOMICS- SPREADSHEETS, DECISION ANALYSIS, INTERNET, AND EDUCATIONAL TOOLS

    May 1, 1999, 00:00

  • TPCT3- COST-EFFECTIVENESS OF ANTIMALARIAL TREATMENT OF QUININE PLUS DOXYCYCLINE VERSUS ARTEMISININ PLUS DOXYCYCLINE IN PHUOC LONG HOSPITAL, VIETNAM

    May 1, 1999, 00:00

  • WMM3- MODELING SEQUENTIAL DECISION-MAKING IN PHARMACOECONOMICS

    May 1, 1999, 00:00

  • PID2- INCREASED COST OF MANAGING AIDS IN THE LAST YEAR OF LIFE

    May 1, 1999, 00:00

  • PCD5- RELIABILITY AND VALIDITY OF THE BREAST EVALUATION QUESTIONNAIRE (BEQ)- AN OUTCOME MEASURE FOR BREAST IMPLANT STUDIES

    May 1, 1999, 00:00

  • PUP2- PHARMACOECONOMIC INFORMATION IN FORMULARY DECISION-MAKING IN THE UNITED STATES

    May 1, 1999, 00:00

  • RM3- THE USE OF ABCIXIMAB FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PATIENTS ENROLLED IN MANAGED CARE ORGANIZATIONS

    May 1, 1999, 00:00

  • PNP14- COST AND UTILIZATION OUTCOMES OF PATIENTS TREATED FOR SCHIZOPHRENIA IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • TPQL7- THE EFFECT OF ORDER OF ADMINISTRATION OF GENERIC AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRES

    May 1, 1999, 00:00

  • PKU4- LINGUISTIC VALIDATION OF THE KINGS HEALTH QUESTIONNAIRE (KHQ) IN EIGHT LANGUAGES

    May 1, 1999, 00:00

  • PWM7- COST-EFFECTIVENESS OF ESTROGEN REPLACEMENT THERAPY (ERT) ON THE PREVENTION OF OSTEOPOROSIS- SHORT-TERM VERSUS LONG-TERM THERAPY

    May 1, 1999, 00:00

  • PCVD9- LEFT VENTRICULAR SYSTOLIC FUNCTION AND DRUG UTILIZATION AMONG HOSPITALIZED PATIENTS WITH CONGESTIVE HEART FAILURE

    May 1, 1999, 00:00

  • PPO7- UTILIZATION OF AMBULATORY CARE SERVICES DUE TO ADVERSE EFFECTS OF MEDICATIONS IN THE UNITED STATES

    May 1, 1999, 00:00

  • PNP9- ANTIDEPRESSANT IMPACT ON SOCIAL FUNCTIONING- REBOXETINE VERSUS FLUOXETINE

    May 1, 1999, 00:00

  • Pharmacoeconomic Perspectives in Russia

    May 1, 1999, 00:00

  • TPRD1- PHARMACOECONOMIC ANALYSIS OF WARFARIN VERSUS ENOXAPARIN USED PROPHYLACTICALLY IN HIP SURGERY

    May 1, 1999, 00:00

  • PCP9- THE ANALGESIC EFFICACY AND THERAPEUTIC ONSET OF ANALGESIA OF INTRAVENOUS AND INTRAMUSCULAR KETOROLAC (15 MG AND 30 MG), AND ORAL IBUPROFEN 800 MG IN THE EMERGENCY ROOM- A COMPARATIVE STUDY

    May 1, 1999, 00:00

  • PCVD3- COST-EFFECTIVENESS OF THROMBOLYTIC AGENTS IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION

    May 1, 1999, 00:00

  • PPO8- AN EMPIRICAL ANALYSIS ON AMBULATORY CARE UTILIZATION- APPLICATION OF A COUNT DATA MODEL

    May 1, 1999, 00:00

  • ER4- MODELING PHARMACOECONOMIC ANALYSES WITH DISTRIBUTIONS OF RESULTS FROM TRIALS

    May 1, 1999, 00:00

  • PUP4- IMPLEMENTATION OF PHARMACOECONOMIC ANALYSIS IN NORWAY. ARE THE USERS PREPARED?

    May 1, 1999, 00:00

  • TPQL1- DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE IN URINARY INCONTINENCE (CONTILIFE)

    May 1, 1999, 00:00

  • TPCP5- THE COST OF DISCONTINUATION OF ANTI-HYPERTENSIVE DRUG THERAPY IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • PCVD2- HYPERTENSION DISEASE MANAGEMENT- A RANDOMIZED, COMPARATIVE TRIAL

    May 1, 1999, 00:00

  • WPE7- SCHIZOPHRENIA- HELPING THE DECISIONMAKER TO UNDERSTAND THE IMPACTS OF ATYPICAL ANTIPSYCHOTICS

    May 1, 1999, 00:00

  • TPIL7- MEDICAL RESOURCE USE AND PAYER COSTS OF INPATIENT AND OUTPATIENT CARE RELATED TO EPILEPSY

    May 1, 1999, 00:00

  • PPR5- ESTIMATING HEALTHCARE COSTS IN THE ABSENCE OF FINANCIAL DATA- A CASE STUDY

    May 1, 1999, 00:00

  • PRD1- BARRIERS TO EFFECTIVE ASTHMA DISEASE MANAGEMENT- LIMITATIONS IN PHYSICIAN KNOWLEDGE OF TREATMENT GUIDELINES

    May 1, 1999, 00:00

  • POR8- MINIMAL STANDARDS FOR THE VALIDATION OF QUALITY OF LIFE INSTRUMENTS USED IN CLINICAL TRIALS

    May 1, 1999, 00:00

  • POR6- EVALUATION OF THE STRUCTURAL VALIDITY OF THE SF-12

    May 1, 1999, 00:00

  • WPE10- GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS- CURRENT USE AND EMERGING TRENDS

    May 1, 1999, 00:00

  • WPE8- DESIGNING NATURALISTIC OUTCOMES TRIALS THAT ARE APPLICABLE TO THE 'REAL WORLD' OF CLINICAL PRACTICE

    May 1, 1999, 00:00

  • TPRD3- OUTCOMES OF TREATMENT OF UNCOMPLICATED HYPERTENSION WITH DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

    May 1, 1999, 00:00

  • WMS4- STATISTICAL ISSUES IN THE DESIGNING AND ANALYZING THE DATA FOR PHARMACOECONOMICS AND OUTCOME STUDIES

    May 1, 1999, 00:00

  • WPE5- ANALYSES OF OUTCOME DOMAINS IN SCHIZOPHRENIA- METHODOLOGIES AND RESULTS FROM THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)

    May 1, 1999, 00:00

  • WMQ3- EVALUATING HIV DISEASE HEALTH OUTCOMES IN DIFFERENT TREATMENT SETTINGS- HOW TO SELECT THE MOST APPROPRIATE HRQL INSTRUMENT

    May 1, 1999, 00:00

  • PRD9- THE HEALTHCARE UTILIZATION OF PATIENTS WITH CHRONIC SINUSITIS

    May 1, 1999, 00:00

  • PG11- COSTS AND PRACTICE PATTERNS ASSOCIATED WITH TREATING GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN A MANAGED CARE POPULATION

    May 1, 1999, 00:00

  • PKU7- COST UTILITY ANALYSIS OF LIVER AND KIDNEY TRANSPLANTATION IN GERMANY

    May 1, 1999, 00:00

  • PAD6- ASSESSMENT OF THE ECONOMIC AND HUMANISTIC OUTCOMES OF THE WEST VIRGINIA MEDICAIDS PRIOR AUTHORIZATION POLICY FOR NSAIDS

    May 1, 1999, 00:00

  • PWM2- EFFECTIVENESS AND COST IMPACT OF EMERGENCY CONTRACEPTION OBTAINED FROM A PHARMACIST IN WASHINGTON STATE

    May 1, 1999, 00:00

  • PNP11- DIABETES MELLITUS AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS RECEIVING ANTIDEPRESSANT DRUGS

    May 1, 1999, 00:00

  • TPIC5- TELEPHONY AS A COST-EFFICIENT METHOD FOR ASSESSING HEALTHCARE UTILIZATION (HCU) AND PRODUCTIVITY LOSS (PL) IN AN EMPLOYED POPULATION

    May 1, 1999, 00:00

  • PPR1- PRE-TEST OF A MARKOV MODEL TO ESTIMATE THE COST OF ILLNESS IN AMBULATORY PATIENTS- A PRELIMINARY ESTIMATE USING PHYSICIAN SURVEY DATA

    May 1, 1999, 00:00

  • PNP20- ANTIPSYCHOTIC UTILIZATION RATIOS- DIFFERENCES AMONG AGE, GENDER, AND PAYER COMBINATIONS

    May 1, 1999, 00:00

  • POR7- DEVELOPING A QUALITY ASSESSMENT SCORING SYSTEM FOR ECONOMIC EVALUATIONS

    May 1, 1999, 00:00

  • WMS3- SOFTWARE FOR COST-EFFECTIVENESS STATISTICAL INFERENCE

    May 1, 1999, 00:00

  • PCD3- COSTS AND OUTCOMES OF HOME VERSUS HOSPITAL-BASED TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY PATIENTS

    May 1, 1999, 00:00

  • PCP7- COSTS AND OUTCOMES OF REGIONAL VERSUS GENERAL VERSUS COMBINATION ANESTHESIA AND ANALGESIA TECHNIQUES IN GREEK PATIENTS UNDERGOING HIP ARTHROPLASTY

    May 1, 1999, 00:00

  • DM3- IMPLEMENTATION OF NATIONAL CHOLESTEROL GUIDELINES- A MULTIDISCIPLINARY APPROACH TO HYPERLIPIDEMIA DISEASE MANAGEMENT

    May 1, 1999, 00:00

  • PCVD12- EFFECTS OF AN EDUCATIONAL CAMPAIGN ON MEDICATION USE FOR CORONARY ARTERY DISEASE (CAD)

    May 1, 1999, 00:00

  • TPDM5- COST-BENEFIT ANALYSIS OF AN INTRAUTERINE LEVONORGESTREL-RELEASING DEVICE MIRENA VERSUS HYSTERECTOMY FOR WOMEN WITH MENORRHAGIA

    May 1, 1999, 00:00

  • PRD7- THE USE OF GENERALIZED ESTIMATING EQUATIONS IN LONGITUDINAL STUDIES OF RESOURCE UTILIZATION- THE CASE OF ASTHMA

    May 1, 1999, 00:00

  • WMS2- PITFALLS WHEN USING REGRESSION EQUATIONS TO ESTIMATE TREATMENT IMPACT IN ACTUAL PRACTICE

    May 1, 1999, 00:00

  • WMM5- USING EPIDEMIOLOGIC DATABASES TO EXTRAPOLATE LONG-TERM OUTCOMES FROM SURROGATE MARKER DATA

    May 1, 1999, 00:00

  • PKU5- ACUTE REJECTION EPISODES ARE ASSOCIATED WITH HIGHER UTILIZATION OF RESOURCES AFTER KIDNEY TRANSPLANTATION

    May 1, 1999, 00:00

  • TPQL6- THE PERFORMANCE OF A GENERIC MEASURE (EQ-5D) IN ASSESSING MENTAL HEALTH OUTCOMES

    May 1, 1999, 00:00

  • PID9- EVALUATION OF THE OUTCOMES OF PATIENTS ON HEMODIALYSIS RECEIVING AMPHOTERICIN B LIPID COMPLEX (ABLC)

    May 1, 1999, 00:00

  • WMD2- THE WHAT, HOW, AND WHY OF THE DELPHI

    May 1, 1999, 00:00

  • POR5- EVALUATION OF THE ANALYTICAL HIERARCHY PROCESS (AHP) AS A TOOL IN FORMULARY DEVELOPMENT

    May 1, 1999, 00:00

  • PDD4- DEVELOPMENT OF HEALTH STATE DESCRIPTIONS OF DIABETIC PERIPHERAL NEUROPATHY FOR A NEW UTILITY INSTRUMENT

    May 1, 1999, 00:00

  • DP1- EFFECT OF DEMOGRAPHICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM

    May 1, 1999, 00:00

  • PCVD16- THE ECONOMIC AND HEALTH BENEFITS OF CONVERSION TO NORMAL SINUS RHYTHM

    May 1, 1999, 00:00

  • PID13- LONG-TERM EFFICACY OF LOCAL GUIDELINES TO IMPROVE ANTITETANUS PROPHYLAXIS AND REDUCE COSTS IN AN EMERGENCY DEPARTMENT

    May 1, 1999, 00:00

  • PCP4- LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE (PPMQ) IN 16 LANGUAGES

    May 1, 1999, 00:00

  • WMQ1- THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM HEALTH QUESTIONNAIRE (SCAP-HQ)- A BRIEF INSTRUMENT TO ASSESS OUTCOMES OF CARE IN SCHIZOPHRENIA

    May 1, 1999, 00:00

  • PWM6- IMPACT OF POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY ON RESOURCE UTILIZATION ASSOCIATED WITH ADVERSE EVENTS

    May 1, 1999, 00:00

  • PCP2- IMPACT OF PATIENT EDUCATION ON QUALITY OF LIFE IN HEADACHE TREATMENT

    May 1, 1999, 00:00

  • PPO11- NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING- OVERVIEW OF THE PROCESS AND PRESENTATION OF DESCRIPTIVE STATISTICS

    May 1, 1999, 00:00

  • PPR6- COST-EFFECTIVENESS ANALYSIS- A SIMULTANEOUS MARGINAL-EFFECT APPROACH

    May 1, 1999, 00:00

  • TPS2- COST ANALYSIS OF A DIAGNOSTIC SCREENING TO DIFFERENTIATE 30- TO 45-YEAR-OLD PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS

    May 1, 1999, 00:00

  • ER1- THE APPLICATION OF MULTILEVEL MODELING AND CLUSTER ANALYSIS TO MULTINATIONAL ECONOMIC EVALUATION DATA

    May 1, 1999, 00:00

  • PUP3- ANALYSIS OF THE ECONOMIC IMPACT OF AN INCREASE IN THE UTILIZATION OF GENERIC MEDICATIONS IN PORTUGAL

    May 1, 1999, 00:00

  • POR1- METHODOLOGY FOR DEVELOPING AN INDEX SCORE FOR BOTHERSOMENESS OF ADVERSE EVENTS

    May 1, 1999, 00:00

  • DP3- USING SIMULATION MODELING TECHNIQUES TO FACILITATE THE MANAGEMENT OF THE WAITING LIST FOR LIVER TRANSPLANTATION

    May 1, 1999, 00:00

  • TPDM2- COST-EFFECTIVENESS OF INCREASING WARFARIN USAGE FOR STROKE PROPHYLAXIS IN PATIENTS WITH ATRIAL FIBRILLATION

    May 1, 1999, 00:00

  • TPS6- COST-EFFECTIVENESS OF SCREENING AND TREATING DIABETIC RETINOPATHY IN TYPE I DIABETICS

    May 1, 1999, 00:00

  • PRD11- QUALITY OF LIFE ASSESSMENT IN ALLERGIC RHINITIS PATIENTS TREATED WITH LORATADINE

    May 1, 1999, 00:00

  • PPO10- UNDERSTANDING THE PROCESS AND ROLE OF TECHNOLOGY ASSESSMENT IN LARGE HEALTH MAINTENANCE ORGANIZATIONS

    May 1, 1999, 00:00

  • WDM3- APPLYING PRACTICAL APPLICATIONS OF PHARMACOECONOMICS AND OUTCOMES e DATA IN THE COMMUNITY HEALTHCARE FACILITY

    May 1, 1999, 00:00

  • PNP23- THE IMPACT OF ALCOHOL CONSUMPTION AND SMOKING ON SHORT-TERM HEALTHCARE COSTS IN A MANAGED CARE POPULATION

    May 1, 1999, 00:00

  • PCP1- A THREE-PHASED DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOID THERAPY FOR CHRONIC PAIN

    May 1, 1999, 00:00

  • PPR7- A FORMAL AUDIT OF 228 PUBLISHED COST-UTILITY ANALYSES

    May 1, 1999, 00:00

  • PPR2- EVALUATION OF AN EDUCATIONAL INTERVENTION ON THE PERCEPTION OF COST-EFFECTIVE INFORMATION RELATIVE TO CLINICAL INFORMATION

    May 1, 1999, 00:00

  • WTG5- EVALUATION OF FORMULARY DECISIONS- PROJECTED IMPACT OF A NEW DRUG ROLLOUT WITHIN THE MANAGED CARE ARENA

    May 1, 1999, 00:00

  • DISCLOSURE INFORMATION

    May 1, 1999, 00:00

  • TPCP6- THE ROLE OF ALTERNATIVE ANTIHYPERLIPIDEMIC DRUGS- PATIENT COMPLIANCE, HEALTHCARE UTILIZATION, AND HEALTHCARE COSTS

    May 1, 1999, 00:00

  • TPCT2- COST-EFFECTIVENESS OF ABCIXIMAB IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS- RESULTS FROM A META-ANALYSIS

    May 1, 1999, 00:00

  • PPO6- TIME-DEPENDENT SURVIVAL ANALYSIS OF A PHARMACISTS CONSULTATION INTERVENTION STUDY

    May 1, 1999, 00:00

  • PDD2- PSYCHOMETRIC PROPERTIES OF THE PATIENT BENEFIT QUESTIONNAIRE (PBQ) IN A COHORT OF DIABETIC PERIPHERAL NEUROPATHY (DPN) PATIENTS

    May 1, 1999, 00:00

  • TPCT5- TREATMENT OF DIABETIC FOOT ULCERS WITH TOPICAL RECOMBINANT GROWTH FACTOR GEL ACHIEVES HIGHER HEALING RATES AND RESULTS IN LOWER PROJECTED COSTS OF CARE

    May 1, 1999, 00:00

  • RM1- CONTROLLING FOR SIMULTANEITY BIAS IN OUTCOME STUDIES USING PANEL DATA

    May 1, 1999, 00:00

  • TPRD7- ESTIMATING LIFE-EXPECTANCY IN POSTACUTE CORONARY SYNDROMES- THE IMPORTANCE OF TWO-COMPONENT SURVIVAL MODELS

    May 1, 1999, 00:00

  • TPCP2- PERCENTAGE OF ANTI-HYPERTENSIVE DRUGS 'FILLED AS INTENDED' COMPARING PHARMACY CLAIMS AND MEDICAL RECORDS DATA

    May 1, 1999, 00:00

  • PCD9- UTILIZATION OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) TREATMENTS AMONG PROSTATE CANCER PATIENTS IN CaPSURE

    May 1, 1999, 00:00

  • PCD6- COMPARISON OF THE McMASTERS HEALTH UTILITIES INDEX-MARK III AND THE EUROQOL-5D IN A SURGICAL BREAST CANCER POPULATION

    May 1, 1999, 00:00

  • WPE3- HEALTH ECONOMISTS AND MANAGED CARE DECISION-MAKERS- BRIDGING THE GAP

    May 1, 1999, 00:00

  • PID8- TREATMENT OF ONYCHOMYCOSIS OF THE NAIL IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • ND2- POTENTIAL SAVINGS IN THE COST OF TREATING ALZHEIMERS DISEASE- PATIENT TREATMENT WITH RIVASTIGMINE

    May 1, 1999, 00:00

  • TPCT4- COST-EFFECTIVENESS OF RABEPRAZOLE VERSUS RANITIDINE IN REFLUX ESOPHAGITIS

    May 1, 1999, 00:00

  • ID2- CHRONIC HEPATITIS C- COST-EFFECTIVENESS OF INTERFERON AND RIBAVIRIN

    May 1, 1999, 00:00

  • TPIC3- THE PRODUCTIVITY COSTS OF ALLERGIC RHINITIS

    May 1, 1999, 00:00

  • PRD8- A RETROSPECTIVE DATABASE STUDY OF PATIENT ADHERENCE WITH ASTHMA TREATMENT REGIMENS

    May 1, 1999, 00:00

  • WMD3- NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING- PROCESS AND TECHNOLOGY

    May 1, 1999, 00:00

  • CD1- HOSPITAL UTILIZATION AND COST AMONG PATIENTS WITH NONISCHEMIC HEART FAILURE IN THE FIRST PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY (PRAISE)

    May 1, 1999, 00:00

  • PKU3- LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE

    May 1, 1999, 00:00

  • PNP13- DEVELOPMENT OF A COST CONSEQUENCES COMPUTER SIMULATION MODEL OF BIPOLAR DISORDER

    May 1, 1999, 00:00

  • WTG4- ECONOMIC EVALUATION OF PHARMACEUTICALS IN ISRAEL- CURRENT AND FUTURE NATIONAL POLICY

    May 1, 1999, 00:00

  • ID1- ESTIMATING THE COST-EFFECTIVENESS OF ANTIBIOTIC TREATMENT FOR ACUTE OTITIS MEDIA USING INSTRUMENTAL VARIABLE ESTIMATION TECHNIQUES

    May 1, 1999, 00:00

  • PCVD13- ASSESSING LIPID-LOWERING INTERVENTIONS IN MANAGED CARE SETTINGS

    May 1, 1999, 00:00

  • TPDM6- DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER

    May 1, 1999, 00:00

  • DM4- COST-EFFECTIVENESS OF OCCUPATIONAL THERAPY ON HEALTHY ELDERLY PEOPLE

    May 1, 1999, 00:00

  • PNP8- DEPRESSION IN POOR, YOUNG WOMEN- FLUOXETINE VERSUS SERTRALINE

    May 1, 1999, 00:00

  • PNP17- ECONOMIC BURDEN DUE TO COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE MANAGEMENT OF PSYCHIATRIC DISORDERS IN INDIA

    May 1, 1999, 00:00

  • PNP19- PSYCHOTROPIC PRESCRIBING FOR THE ELDERLY IN AMBULATORY CLINICS

    May 1, 1999, 00:00

  • PNP6- COST-BENEFIT ANALYSIS OF ORAL ANTIDEPRESSANTS IN THE MANAGEMENT OF MAJOR DEPRESSIVE DISORDER- A MANAGED CARE PERSPECTIVE

    May 1, 1999, 00:00

  • PID19- COST-EFFECTIVENESS OF ONCE-DAILY CLARITHROMYCIN COMPARED TO AMOXYCILLIN/CLAVULANIC ACID IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

    May 1, 1999, 00:00

  • PAD5- RETROSPECTIVE EVALUATION OF CONCOMITANT GASTROINTESTINAL DRUG USE WITH NSAID THERAPY AMONG PATIENTS WITH ARTHRITIS

    May 1, 1999, 00:00

  • PNP5- PHARMACOECONOMIC ANALYSIS OF PATTERNS OF ANTIDEPRESSANT USE

    May 1, 1999, 00:00

  • RD1- TREATING ALLERGIC RHINITIS IN PATIENTS WITH COMORBID ASTHMA- THE RISK OF ASTHMA-RELATED HOSPITALIZATIONS AND EMERGENCY ROOM VISITS

    May 1, 1999, 00:00

  • Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion

    Mar 1, 1999, 00:00

  • Panel 6- Addressing Questions of Bias, Credibility, and Quality in Health Economic Evaluations

    Mar 1, 1999, 00:00

  • Pharmacoeconomics- Identifying the Issues Overview and Advisory Panel Report Summary

    Mar 1, 1999, 00:00

  • Panel 4- Education and Skills Needed to Conduct, Interpret, and Use Economic Evaluations in Healthcare

    Mar 1, 1999, 00:00

  • Resources Used by Panelists

    Mar 1, 1999, 00:00

  • Panel 5- Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making

    Mar 1, 1999, 00:00

  • Panel 3- Methodological Issues in Conducting Pharmacoeconomic Evaluations—Retrospective and Claims Database Studies

    Mar 1, 1999, 00:00

  • Panel 1- Methodological Issues in Pharmacoeconomic Evaluations—Clinical Studies

    Mar 1, 1999, 00:00

  • Panel 2- Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling Studies

    Mar 1, 1999, 00:00

  • Panel 7- Communication and Reporting Health Economic Information

    Mar 1, 1999, 00:00

  • W3- ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS

    Jan 1, 1999, 00:00

  • PCA7- COST ESTIMATION OF SEVERE NEUTROPENIA IN BELGIUM

    Jan 1, 1999, 00:00

  • PCA10- THE RELATIONSHIP BETWEEN PROFILE-BASED QUALITY OF LIFE SCORES AND EUROQOL-5D SCORES IN BREAST CANCER SURGERY PATIENTS

    Jan 1, 1999, 00:00

  • PGIU2- EVALUATING CLINICAL OUTCOMES OF GERD TREATMENT OPTIONS USING DECISION ANALYSIS

    Jan 1, 1999, 00:00

  • W2- ESTIMATING DRUG EFFECTS- FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE

    Jan 1, 1999, 00:00

  • CV2- COST-EFFECTIVENESS OF TREATING HIGH-RISK INDIVIDUALS, AGED 45-65, WITH STATINS IN GERMANY FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE

    Jan 1, 1999, 00:00

  • PCV1- COST-EFFECTIVENESS OF LIPID MODULATOR AGENTS

    Jan 1, 1999, 00:00

  • IM1- ASSESSING THE VALUE OF EPOETIN-a VERSUS AUTOLOGOUS BLOOD DONATION IN ORTHOPEDIC SURGERY- A FEASIBILITY STUDY OF CONTINGENT VALUATION

    Jan 1, 1999, 00:00

  • L3- QUALITY OF LIFE OF ASTHMA PATIENTS RELATIVE TO ASTHMA SEVERITY

    Jan 1, 1999, 00:00

  • PMC1- MEDICATION COMPLIANCE AND EXPENDITURE IMPACT ASSOCIATED WITH PHARMACISTS COGNITIVE SERVICE INTERVENTIONS

    Jan 1, 1999, 00:00

  • PMH2- CLINICAL AND ECONOMIC CHARACTERIZATION OF FAMILY MEDICINE PATIENTS RECEIVING ANTIDEPRESSANT DRUGS

    Jan 1, 1999, 00:00

  • PN2- RESULTS OF DISEASE MANAGEMENT IN HEADACHE TREATMENT

    Jan 1, 1999, 00:00

  • W19- THE BOOTSTRAP STATISTICAL METHOD FOR THE PHARMACOECONOMIC COST ANALYSIS OF SKEWED DATA

    Jan 1, 1999, 00:00

  • J2- REVIEW OF LEGISLATION RELATING TO PROMOTION OF MEDICINAL PRODUCTS IN THE EUROPEAN UNION-ARE HEALTH ECONOMICS DATA COVERED?

    Jan 1, 1999, 00:00

  • MH4- ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIORS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY IN FRANCE- I. EPIDEMIOLOGY

    Jan 1, 1999, 00:00

  • W5- A NATURAL HISTORY OF ALZHEIMERS DISEASE- PATH-DEPENDENT EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES USING DECISION DATABASE METHODOLOGY

    Jan 1, 1999, 00:00

  • W15- SELF-REPORTED RESOURCE UTILIZATION DATA IN PHARMACOECONOMIC TRIALS- THEIR USE AND IMPACT ON STUDY VALIDITY

    Jan 1, 1999, 00:00

  • PMH4- THE BUDGET IMPACT PHARMACOTHERAPY SELECTION FOR MAJOR DEPRESSIVE DISORDER- A MULTINATIONAL STUDY

    Jan 1, 1999, 00:00

  • Wl- THE DARTS DIABETES DATABASE- HOW CAN QUALITY OF LIFE MEASUREMENTS FOR OUTCOMES RESEARCH BE INCORPORATED?

    Jan 1, 1999, 00:00

  • PMH3- COST-EFFECTIVENESS OF FLUVOXAMINE IN THE TREATMENT OF RECURRENT DEPRESSION IN FRANCE

    Jan 1, 1999, 00:00

  • PMH1- ANNUAL DIRECT COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS IN INDIA

    Jan 1, 1999, 00:00

  • PID2- COST-MINIMIZATION ANALYSIS OF CEFAMANDOLE AND TOBRAMYCIN VERSUS STANDARD THERAPY IN THE TREATMENT OF PATIENTS WITH LOCAL APPENDICULAR PERITONITIS

    Jan 1, 1999, 00:00

  • W11- DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)

    Jan 1, 1999, 00:00

  • CV1- PRELIMINARY QUALITY-OF-LIFE EVALUATION OF THE GERMAN SAT TRIAL- COMPARISON OF SF-36, EUROQOL, TIME TRADE-OFF METHOD, AND WILLINGNESS TO PAY METHOD

    Jan 1, 1999, 00:00

  • CV3- UTILIZATION OF ACE INHIBITORS IN CONGESTIVE HEART FAILURE AMONG THE ELDERLY IN QUEBEC

    Jan 1, 1999, 00:00

  • PGIU1- WILLINGNESS TO PAY OF PATIENTS WITH PAINFUL-IRRITABLE BLADDER SYNDROME

    Jan 1, 1999, 00:00

  • PCA8- COST-MINIMIZATION IN THE USE OF COLONY-STIMULATING FACTORS (CSFs) BASED ON CLINICAL PREDICTION MODELS (CPMs)

    Jan 1, 1999, 00:00

  • PMC2- RUNNING COST OF TREATING A PATIENT IN A GENERAL MEDICAL WARD IN SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN

    Jan 1, 1999, 00:00

  • Mission Statement and Objectives

    Jan 1, 1999, 00:00

  • MH1- ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED WITH BENZODIAZEPINE USE

    Jan 1, 1999, 00:00

  • PMC7- DIMINISHING THE COST OF HIGHLY PRESCRIBED DRUGS IN THE COMUNIDAD VALENCIANA (SPAIN)

    Jan 1, 1999, 00:00

  • MH2- NEW BENZODIAZEPINE USE IS ASSOCIATED WITH AN AGE-RELATED RISK OF HOSPITALIZATION WITH FRACTURE AND OTHER TRAUMA- A POPULATION-BASED STUDY

    Jan 1, 1999, 00:00

  • PN1- A UK PRIMARY CARE DATABASE (UKPCD)-UK MEDIPLUS AS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE INCIDENCE AND PREVALENCE OF MULTIPLE SCLEROSIS, ITS TREATMENT, PRESCRIPTION COSTS, AND REFERRALS IN UK PRACTICE

    Jan 1, 1999, 00:00

  • PN6- IMPACT OF A COST-SHARING DRUG INSURANCE PLAN ON DRUG UTILIZATION AMONG INDIVIDUALS RECEIVING SOCIAL ASSISTANCE

    Jan 1, 1999, 00:00

  • ND3- ECONOMIC EVALUATION OF ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL-DEPENDENT PATIENTS

    Jan 1, 1999, 00:00

  • PCA5- QUALITY OF LIFE IN HODGKINS DISEASE- RESULTS FROM THE EORTC AND GHSG TRIALS

    Jan 1, 1999, 00:00

  • PN5- CROSS-CULTURAL ADAPTATION OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS) QUESTIONNAIRE IN NINE COUNTRIES

    Jan 1, 1999, 00:00

  • CV4- IMPROVED MYOCARDIAL PROTECTION DURING CORONARY BYPASS SURGERY SHORTENS HOSPITAL STAY AND SAVES COSTS

    Jan 1, 1999, 00:00

  • PMC6- ADVANCED SENSITIVITY ANALYSIS BY THE INTEGRATION OF POINT-SENSITIVITY AND RANGE-SENSITIVITY USING PROBABILITY DISTRIBUTIONS

    Jan 1, 1999, 00:00

  • W18- HEALTH STATUS AND QUALITY OF LIFE MEASURES IN INTERNATIONAL CLINICAL RESEARCH

    Jan 1, 1999, 00:00

  • CAN1- COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY TREATMENT FOR METASTATIC BREAST CANCER

    Jan 1, 1999, 00:00

  • PCIU4- CROSS-CULTURAL ADAPTATION OF THE PATIENT ASSESSMENT OF CONSTIPATION-SYMPTOM QUESTIONNAIRE (PAC-SYM)

    Jan 1, 1999, 00:00

  • PMH8- EFFECT OF RISPERIDONE ON THE COST OF NURSING HOME CARE FOR RESIDENTS WITH BEHAVIORAL AND PSYCHOLOGICAL SIGNS AND SYMPTOMS

    Jan 1, 1999, 00:00

  • PCV10- A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM

    Jan 1, 1999, 00:00

  • D2- PATIENT-HELD INSTRUMENTS FOR RECORDING AMBULATORY CARE RESOURCE USE- EXPERIENCE IN PATIENTS WITH DIABETIC FOOT ULCERS

    Jan 1, 1999, 00:00

  • Wl2- DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES

    Jan 1, 1999, 00:00

  • PN7- COST-EFFECTIVENESS OF PRAMIPEXOLE IN PARKINSONS DISEASE IN THREE COUNTRIES

    Jan 1, 1999, 00:00

  • PCIU3- THE EFFECTS OF ULCER-HEALING DRUG COPRESCIPTION ON NSAID-INDUCED GASTROINTESTINAL EVENTS- A RECORD LINKAGE COHORT STUDY

    Jan 1, 1999, 00:00

  • L2- EFFECTIVENESS OF ORAL CIPROFLOXACIN IN THE TREATMENT OF EXACERBATIONS OF CHRONIC AIRWAY DISEASES

    Jan 1, 1999, 00:00

  • PCIU5- RATE OF GASTROPROTECTIVE AGENT USE, DIAGNOSTIC TESTS, AND HOSPITALIZATIONS AMONG ELDERLY PATIENTS WHO STARTED ARTHROTEC, A FIXED COMBINATION OF MISOPROSTOL AND DICLOFENAC

    Jan 1, 1999, 00:00

  • ID1- IS TRIMETHOPRIM RESISTANCE AN OUTCOME OF COMMUNITY ANTIBIOTIC PRESCRIBING?

    Jan 1, 1999, 00:00

  • ISPOR Inaugural European Conferen An Overview

    Jan 1, 1999, 00:00

  • PIM1- COST-EFFECTIVENESS ANALYSIS OF A FIXED COMBINATION (DICLOFENAC 1 MISOPROSTOL) IN THE PREVENTION OF GASTROPATHY IN ARTHRITIS PATIENTS IN BELGIUM

    Jan 1, 1999, 00:00

  • CV5- ECONOMIC ASSESSMENT OF A PROPHYLACTIC TREATMENT OF RECURRENCE OF ISCHEMIC ACCIDENTS BY LYSINE ACETYLSALICYLATE

    Jan 1, 1999, 00:00

  • W8- THE DEVELOPMENT AND IMPLEMENTATION OF FORMULARY SUBMISSION GUIDELINES FOR MANAGED CARE IN THE UNITED STATES

    Jan 1, 1999, 00:00

  • Invited Speaker Biographical Summaries

    Jan 1, 1999, 00:00

  • PCV7- CROSS-CULTURAL ADAPTATION OF THE SEATTLE ANGINA QUESTIONNAIRE (SAQ) IN I I COUNTRIES

    Jan 1, 1999, 00:00

  • Welccome

    Jan 1, 1999, 00:00

  • PID1- COST-EFFECTIVENESS OF LEVOFLOXACIN VERSUS CLARITHROMYCIN IN PATIENTS EVALUABLE FOR CLINICAL EFFICACY IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS

    Jan 1, 1999, 00:00

  • D4- MEASURING THE IMPACT OF DIABETIC FOOT ULCERS ON QUALITY OF LIFE FROM THE PATIENTS PERSPECTIVE

    Jan 1, 1999, 00:00

  • PCA9- QUALITY OF LIFE (QOL) OF PATIENTS WITH LOW-GRADE NON-HODGKINS LYMPHOMA (IG-NHL) TREATED WITH FLUDARABINE (F) OR CYCLOPHOSPHAMIDE-VINCRISTINE-PREDNISONE (CVP)

    Jan 1, 1999, 00:00

  • MH5- ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIORS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY IN FRANCE- 2. COST ANALYSIS

    Jan 1, 1999, 00:00

  • PCA1- PHARMACOECONOMIC EFFICIENCY OF THE USE OF PROTEASE INHIBITORS FOR HOSPITAL INPATIENTS WITH AIDS

    Jan 1, 1999, 00:00

  • PCV6- MEASURING DISEASE-SPECIFIC SYMPTOM IMPACT- DEVELOPMENT OF THE ATRIAL FIBRILLATION IMPACT SCALE (AFIS)

    Jan 1, 1999, 00:00

  • PIM3- QUALITY OF LIFE SCORES AS PREDICTORS OF FUTURE HEALTHCARE RESOURCE USE IN PATIENTS WITH ARTHRITIS

    Jan 1, 1999, 00:00

  • PMH7- CROSS-CULTURAL ADAPTATION OF THE INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) IN 31 COUNTRIES

    Jan 1, 1999, 00:00

  • ABSTRACT CONTRIBUTOR STATEMENTS OF FINANCIAL SUPPORT

    Jan 1, 1999, 00:00

  • MH6- COST-UTILITY ANALYSIS OF RISPERIDONE IN CHRONIC SCHIZOPHRENIA

    Jan 1, 1999, 00:00

  • Index

    Jan 1, 1999, 00:00

  • PCA4- OUTCOME OF MONOCLONAL ANTIBODY 17-IA ADJUVANT THERAPY OF RESECTED COLON CANCER DUKES C IN GERMANY- A SUBGROUP ANALYSIS

    Jan 1, 1999, 00:00

  • W10- PRO AND CON- USE OF DATA FROM FOREIGN PHARMACOECONOMIC INVESTIGATIONS IN RUSSIA

    Jan 1, 1999, 00:00

  • PCA2- THE COST-EFFECTIVENESS OF ITRACONAZOLE SOLUTION IN THE TREATMENT OF ORAL CANDIDIASIS IN HIV/AIDS PATIENTS- AN INTERNATIONAL COMPARISON

    Jan 1, 1999, 00:00

  • PMC3- SURVIVAL GAINS AND DEGREE OF THERAPEUTIC INNOVATION

    Jan 1, 1999, 00:00

  • PMC5- USING A SURROGATE SAMPLE TO DERIVE PATIENT PREFERENCES FOR A COST-UTILITY ANALYSES IN A RANDOMIZED CLINICAL TRIAL

    Jan 1, 1999, 00:00

  • MH3- ASSESSING THE SASKATCHEWAN DATABASE FOR OUTCOMES STUDIES OF DEPRESSION AND ITS TREATMENT

    Jan 1, 1999, 00:00

  • PN3- A FOUNDATION STUDY FOR COSTEFFECTIVENESS ANALYSIS- THE DEFINITION OF ECONOMIC PARAMETERS AND CLINICAL ENDPOINTS IN PARKINSONS DISEASE

    Jan 1, 1999, 00:00

  • PCV9- COMPARISON OF THE EPIDEMIOLOGY AND COSTS ASSOCIATED WITH PRIMARY PREVENTION OF CORONARY HEART DISEASE IN FIVE EUROPEAN COUNTRIES

    Jan 1, 1999, 00:00

  • PMC8- META-ANALYSIS OF ECONOMIC EVALUATIONS- A METHODOLOGICAL APPROACH AND CASE STUDY

    Jan 1, 1999, 00:00

  • CAN3- PRACTICE PATTERNS OF CHEMOTHERAPY USAGE AND ASSOCIATED NEUTROPENIA AND FEBRILE NEUTROPENIA (FN) IN EUROPE

    Jan 1, 1999, 00:00

  • PD1- COMPLIANCE WITH AMERICAN DIABETIC ASSOCIATION (ADA) RECOMMENDATIONS IN A TYPE 2 DIABETIC POPULATION IN AN ACADEMIC FAMILY MEDICINE CENTER

    Jan 1, 1999, 00:00

  • IM2- EPOETIN- REDUCES POSTOPERATIVE LENGTH OF STAY IN PATIENTS UNDERGOING KNEE REPLACEMENT

    Jan 1, 1999, 00:00

  • GI1- COST-UTILITY ANALYSIS OF LAPAROSCOPIC VERSUS OPEN SURGERY FOR COLONIC DISEASE

    Jan 1, 1999, 00:00

  • PCV2- ADAPTING ECONOMIC ANALYSES FROM ONE COUNTRY TO ANOTHER- DO THE WOSCOPS UK FINDINGS HOLD IN BELGIUM?

    Jan 1, 1999, 00:00

  • D3- ANTITHYROID DRUGS OR RADIOIODINE AS FIRST-LINE THERAPY OF GRAVES HYPERTHYROIDISM IN A COUNTRY WITH STRICT REGULATIONS FOR RADIATION PROTECTION?

    Jan 1, 1999, 00:00

  • W9- ECONOMIC EVALUATION OF REHABILITATION PROGRAMS- THE PERSPECTIVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY

    Jan 1, 1999, 00:00

  • D1- SELF-MONITORING OF BLOOD GLUCOSE IN DIABETES- IS IT WORTH IT?

    Jan 1, 1999, 00:00

  • J1- IDENTIFYING INITIAL DIAGNOSIS IN DATABASE RESEARCH

    Jan 1, 1999, 00:00

  • PN4- QUALITY OF LIFE AND FUNCTIONAL STATUS MEASURES IN ADVANCED PARKINSONS PATIENTS TREATED WITH PRAMIPEXOLE, BROMOCRIPTINE, OR PLACEBO

    Jan 1, 1999, 00:00

  • PMC4- LINKING HRQOLS TO LARGE NATIONAL DATA SETS- EUROQOL AND HUI INDICES

    Jan 1, 1999, 00:00

  • W13- THE USE OF PROXIES TO COLLECT HEALTHCARE RESOURCES AND QUALITY OF LIFE DATA

    Jan 1, 1999, 00:00

  • W20- STANDARD PROCEDURES FOR ECONOMIC EVALUATION- USING A COMPUTER PROGRAM FOR REPORTING ECONOMIC EVALUATIONS RESULTS (REER)

    Jan 1, 1999, 00:00

  • L1- COMPLIANCE WITH INHALED CORTICOSTEROIDS AND HOSPITALIZATION FOR ASTHMA

    Jan 1, 1999, 00:00

  • PIM2- COST OF ILLNESS IN EARLY RHEUMATOID ARTHRITIS STRATIFIED FOR SOCIAL STATUS

    Jan 1, 1999, 00:00

  • GI3- THE EFFECT OF AN OPEN ACCESS ENDOSCOPY SERVICE ON PRESCRIBING COSTS OF ULCER-HEALING DRUGS

    Jan 1, 1999, 00:00

  • PCV4- THE ECONOMIC IMPACT OF HYPERTENSION STUDY FROM THE PISTOIA PROJECT

    Jan 1, 1999, 00:00

  • L4- CROSS-CULTURAL ADAPTATION OF THE PEDIATRIC ASTHMA CAREGIVER QUALITY OF LIFE QUESTIONNAIRE (PACQLQ) IN 19 COUNTRIES

    Jan 1, 1999, 00:00

  • ND4- CROSS-CULTURAL ADAPTATION OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ) IN 14 LANGUAGES

    Jan 1, 1999, 00:00

  • W6- THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES- RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECONOMIC ANALYSES

    Jan 1, 1999, 00:00

  • PCV5- POTENTIAL COST SAVINGS OF THE 4 FRENCH INFINITI CATHETER IN DIAGNOSTIC CORONARY ANGIOGRAPHY

    Jan 1, 1999, 00:00

  • WI7- STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA- THE FIRST EXPERIENCE

    Jan 1, 1999, 00:00

  • ND1- AN 11-YEAR, CONTROLLED STUDY OF HEALTHCARE RESOURCE USE AND MORTALITY FOR PATIENTS WITH PARKINSONS DISEASE

    Jan 1, 1999, 00:00

  • GI2- DIGEST INTERNATIONAL SURVEY- IMPACT OF UPPER GASTROINTESTINAL SYMPTOMS ON RESOURCE UTILIZATION AND QUALITY OF LIFE

    Jan 1, 1999, 00:00

  • ID2- CIPROFLOXACIN IS MORE SUCCESSFUL AND COST-EFFECTIVE THAN TRIMETHOPRIM/SULFAMETHOXAZOLE IN THE ORAL AMBULATORY TREATMENT OF WOMEN WITH UNCOMPLICATED ACUTE PYELONEPHRITIS

    Jan 1, 1999, 00:00

  • PP3- INCREMENTAL COST OF DISEASE IN NOSOCOMIAL PNEUMONIA FROM A HOSPITALS PERSPECTIVE- A FEASIBILITY STUDY

    Jan 1, 1999, 00:00

  • PP1- CHARACTERISTICS OF CHRONIC AIRWAY DISEASE PATIENTS STARTED ON NEBULIZED IPRATROPIUM SOLUTION

    Jan 1, 1999, 00:00

  • PCA6- COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER

    Jan 1, 1999, 00:00

  • W7- HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS

    Jan 1, 1999, 00:00

  • CAN2- A NEW METHOD FOR EXPRESSING SURVIVAL AND LIFE EXPECTANCY IN CANCER PATIENTS

    Jan 1, 1999, 00:00

  • PCV3- EFFICACY OF CARDIAC REHABILITATION THERAPY- A PROSPECTIVE MULTICENTER COHORT STUDY

    Jan 1, 1999, 00:00

  • W14- DESIGNING AN INTERNATIONAL PIGGYBACK STUDY- PROVIDING THE FOUNDATION

    Jan 1, 1999, 00:00

  • PMH6- DEVELOPMENT OF A NEW DISEASE-SPECIFIC QUALITY OF LIFE SCALE FOR USE IN SCHIZOPHRENIA

    Jan 1, 1999, 00:00

  • CV6- OUTCOME OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH MAXIMAL INDIVIDUAL THERAPY (MITRA-STUDY)

    Jan 1, 1999, 00:00

  • PP2- THE EFFECT OF AGE ON COST-EFFECTIVENESS IN THE TREATMENT OF MODERATE ASTHMA

    Jan 1, 1999, 00:00

  • PP4- ECONOMIC IMPACT OF SMOKING IN GERMANY

    Jan 1, 1999, 00:00

  • J3- HOW DO PATIENTS MAKE SATISFACTION JUDGMENTS? ANSWERS FROM STRUCTURAL EQUATION MODELING

    Jan 1, 1999, 00:00

  • W4- MONTE CARLO SIMULATION IN HEALTHCARE MODELS

    Jan 1, 1999, 00:00

  • PCA3- ECONOMIC CONSEQUENCES OF MONOCLONAL ANTIBODY 17-1A ADJUVANT THERAPY OF RESECTED DUKES C COLORECTAL CARCINOMA IN GERMANY

    Jan 1, 1999, 00:00

  • PMH5- COST OF ALZHEIMERS DISEASE CARE IN THE UNITED KINGDOM

    Jan 1, 1999, 00:00

  • PCV8- IMPACT OF CLINICAL SENSITIVITY ANALYSIS IN AN EVALUATION OF PRIMARY PREVENTION OF CORONARY HEART DISEASE IN GERMANY

    Jan 1, 1999, 00:00

  • From Research into Practice- How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum

    Nov 1, 1998, 00:00

  • Willingness to Pay versus Willingness to Buy- What Defines Value in Healthcare?

    Nov 1, 1998, 00:00

  • What Is Happening in the Real World in Lipid Therapy and Is It Appropriate? The Need for a Paradigm Shift

    Nov 1, 1998, 00:00

  • A Managed Care Perspective

    Nov 1, 1998, 00:00

  • A Canadian Perspective

    Nov 1, 1998, 00:00

  • Prevalence-Based Economic Evaluation

    Nov 1, 1998, 00:00

  • Employer and Consumer Perspectives

    Nov 1, 1998, 00:00

  • A Pharmacy Benefit Manager Perspective

    Nov 1, 1998, 00:00

  • Criteria for the Economic Evaluation of Lipid Studies in Health Systems

    Nov 1, 1998, 00:00

  • Patient Education and Compliance- How to Make It Cost-Effective

    Nov 1, 1998, 00:00

  • A US Military Perspective

    Nov 1, 1998, 00:00

  • Commentary on Langley and McKenney Papers

    Nov 1, 1998, 00:00

  • A UK Perspective

    Nov 1, 1998, 00:00

  • Economic Modeling and Sensitivity Analysis

    Sep 1, 1998, 00:00

  • Clinical Trials and External Validity

    Sep 1, 1998, 00:00

  • The Economics of Hypercholesterolemia and Lipid-Lowering Therapy- A Brief Historical Tour

    Sep 1, 1998, 00:00

  • Methodology Issues in Lipid Pharmacoeconomic Investigations. Reactor Panel and Open Forum

    Sep 1, 1998, 00:00

  • Compliance in the Real World

    Sep 1, 1998, 00:00

  • The ISPOR Lipid Conferen Pharmacoeconomics and Outcomes Modeling Issues

    Sep 1, 1998, 00:00

  • Lipid-Lowering Pharmacoeconomic Studies. Reactor Panel and Open Forum

    Sep 1, 1998, 00:00

  • Use of Surrogate Measures in Cost-Effectiveness Analyses of Lipid-Lowering Therapies

    Sep 1, 1998, 00:00

  • A Direction for Value in Health

    Sep 1, 1998, 00:00

  • Cardiovascular Disease and Lipoproteins- Available Evidence and Remaining Questions. Reactor Panel and Open Forum

    Jul 1, 1998, 00:00

  • Landmark Trials in Lipid Reduction

    Jul 1, 1998, 00:00

  • Introduction to the ISPOR Lipid Conference

    Jul 1, 1998, 00:00

  • Prevention of Heart Disease- Is LDL Reduction the Outcome of Choice? No, There Is More

    Jul 1, 1998, 00:00

  • Lipoproteins and Cardiovascular Disease- Biological Basis and Epidemiological Studies

    Jul 1, 1998, 00:00

  • Proceedings of the ISPOR Lipid Confren Pharmacoeconomics and Outcomes Research Issues of Lipid Therapy. The First General Session- Cardiovascular Disease and Lipoproteins- Available Evidence and Remaining Questions

    Jul 1, 1998, 00:00

  • Prevention of Heart Disease- Is LDL Reduction the Outcome of Choice? Absolutely Yes

    Jul 1, 1998, 00:00

  • Atherosclerosis, Acute Coronary Events, and Cholesterol-Lowering- A New Paradigm

    Jul 1, 1998, 00:00

  • Health and Economic Outcomes Modeling Practices- A Suggested Framework

    Jul 1, 1998, 00:00

  • ID4 Evaluation of the Cost-Effectiveness of Management Strategies in Cytomegalovirus Infection And Disease

    May 1, 1998, 00:00

  • PCV21 Cost Consequences of Acute Myocardial Infarction in Diabetic Patients-The First Year

    May 1, 1998, 00:00

  • PCV18 The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure

    May 1, 1998, 00:00

  • MGB3 Postmarketing Outcomes Studies- Benefits And Risks

    May 1, 1998, 00:00

  • CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates

    May 1, 1998, 00:00

  • PGD1 The Effects of Community-Based Pharmaceutical Care Services on Asthma-Related Quality of Life

    May 1, 1998, 00:00

  • PMH14 Schizophrenia Management- Does Managed Care Influence Length of Stay in U.S. Hospitals?

    May 1, 1998, 00:00

  • MGA1 Improving Clinical Outcomes by Integrating A Normalized, Standardized, Comparative Database into the Process of Clinical Quality Improvement

    May 1, 1998, 00:00

  • PMH11 Utlization Review of SSRI Therapy at A Mental Health Managed Care Organization

    May 1, 1998, 00:00

  • PHB5 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Osteoarthritis

    May 1, 1998, 00:00

  • PIC1 Markov Chain Estimation of Life Expectancy of HIV-Infected Patients- Comparison of Two Treatment Alternatives

    May 1, 1998, 00:00

  • MHC3 Factors Predicting Potentially Inappropriate Psychotropic Prescribing for the Elderly

    May 1, 1998, 00:00

  • CVA1 Economic Outcomes of Carotid Endrterectomy for Stroke

    May 1, 1998, 00:00

  • PHB3 Psychometric Evaluation of SF-12 in Osteoarthritis Clinical Trials

    May 1, 1998, 00:00

  • CVA2 Cost-Effectiveness and Economic Efficiency- The Case of Statin Therapy in Secondary Prevention of Cornary Heart Disease

    May 1, 1998, 00:00

  • CC3 Modeling Side Effect Costs from Literature-Based Data- Steroid-Induced Side Effects in Renal Transplantation

    May 1, 1998, 00:00

  • PGD3 Cost-Utility Relation of the Treatment of Diabetic Foot Lesion with Hyperbaric Oxygene Therapy Versus Standard Therapy

    May 1, 1998, 00:00

  • PIC8 Clinical And Economic Benefits of An Infectious Disease Approval Program

    May 1, 1998, 00:00

  • MHA6 Evaluation of Antidepressant Utilization Patterns and Associated Depression Diagnoses among Patients in A National Managed Care Organization

    May 1, 1998, 00:00

  • PMD6 Chronic Care Costs of New Medicare HMO Enrollees- Implications for Disease Management

    May 1, 1998, 00:00

  • MHA3 Comparison of Sumatriptan (IMITREX) and Over-the-Counter (OTC) Medication Use According to Migraine Severity

    May 1, 1998, 00:00

  • PGD11 Validity And Reliability of An American Translation of the St. Georges Respiratory Questionnaire

    May 1, 1998, 00:00

  • PMH7 A General Model of the Effects of Alternative Sedative-Hypnotic Agents on the Costs of Motor Vehicle Accidents

    May 1, 1998, 00:00

  • MHA5 SSRI Antidepressant Use in Primary Care in the United Kingdom- A Multivariate Analysis

    May 1, 1998, 00:00

  • CM1 Estimating the Costs And Outcomes for Different Disease Management Strategies- A Case Study of Cyomegalovirus Infection And Disease

    May 1, 1998, 00:00

  • CM5 Discounting Health Benefits in Pharmacoeconomic Analyses- Is It Justified?

    May 1, 1998, 00:00

  • PMD13 Application of Pharmacoeconomics And Outcomes Research in Formulary Decision-Making

    May 1, 1998, 00:00

  • MM3 Development of Drug Use Performance Models as Measures of Patient Care

    May 1, 1998, 00:00

  • PMD12 The Paradox of League Tables

    May 1, 1998, 00:00

  • PCV20 Convenience Implications of A Single Bolus Thrombolytic

    May 1, 1998, 00:00

  • PHB7 The Direct Medical Cost of Osteporotic Fractures

    May 1, 1998, 00:00

  • CC5 Incremental Cost-Effectiveness Analysis Comparing 4-Layer Bandage System with And without Apligraf for the Outpatient Treatment of Venous Leg Ulcers

    May 1, 1998, 00:00

  • ID3 Prescribing Patterns for Treatment of Upper Respiratory Infections

    May 1, 1998, 00:00

  • DA4 Construction of A Validated, Normalized, Granular Administrative Database And Its Use in Clinical Outcomes Improvement, Clinical Research, And Pharmacoeconomic Research

    May 1, 1998, 00:00

  • PMH2 Assessment of Health-Related Quality of Life During Treatment of Opiate Dependence Using the Short Form-36

    May 1, 1998, 00:00

  • PMH3 Evaluation of Humanistic Outcomes for Patients on Selective Serotonin Reuptake Inhibitors

    May 1, 1998, 00:00

  • PMD10 The Development of A Patient Outcomes Software for Urologists- Capsure POS

    May 1, 1998, 00:00

  • PGD8 Comparison of Prevalence Rates of Low Back Disorders Obtained from Two Large National Claims Databases

    May 1, 1998, 00:00

  • PIC6 Using A Pneumonia-Specific Severity of Illness Model in Assessing Variation in Hospital Length of Stay for Community-Acquired Pneumonia Patients

    May 1, 1998, 00:00

  • CVA6 Confounding by Indication in Calcium Channel Blocker Treatment of Hypertension or Angina

    May 1, 1998, 00:00

  • MM4 Reconciling Decision Models with the Real World- The Cost-Effectiveness of Erythropoietin for Esrd-Related Anemia

    May 1, 1998, 00:00

  • PIC7 Epoetin Alfa Administered to Academic Health Center Dialysis Patients- Comparison to HCFA Billing Records

    May 1, 1998, 00:00

  • UT3 The EuroQoL EQ-5D- An Outcome Measure for Use in Clinical And Economic Evaluation

    May 1, 1998, 00:00

  • PCV19 Evaluation of the Costs of Heart Failure in Belgium

    May 1, 1998, 00:00

  • PCV9 Study of Hypertensive Prescribing Practices

    May 1, 1998, 00:00

  • MHA4 SSRI Antidepressant Use Patterns and their Relation to Clinical Global Impressions Scores- A Naturalistic Study

    May 1, 1998, 00:00

  • PGD15 Veterans Satisfaction with H2-Receptor Antagonist (H2RA) Drug Conversion

    May 1, 1998, 00:00

  • PMH9 Month-to-Month Adherence with Antipsychotic Pharmacotherapy- A Comparison Between Atypical And Typical Antipsychotics

    May 1, 1998, 00:00

  • ID1 Randomised Prospective Study Comparing Cost-Effectiveness of Teicoplanin and Vancomycin As Second-Line Empiric Therapy for Infection in Neutropenic Patients

    May 1, 1998, 00:00

  • DA2 The Role of Patient Registries in Disease Management and Outcomes Research

    May 1, 1998, 00:00

  • PIC9 The Economic Impact of A Drug Information Service

    May 1, 1998, 00:00

  • DA8 Evaluating Health Outcomes And Pharmacoeconomic Literature

    May 1, 1998, 00:00

  • PMD9 Evaluation of A Pathway for Providing Pharmaceutical Care

    May 1, 1998, 00:00

  • PMD1 Information Technology in A Large Multi-Site Outcomes Study

    May 1, 1998, 00:00

  • MHB3 Cost-Effectiveness Evaluation of New Antipsychotics

    May 1, 1998, 00:00

  • CC6 Development of Asthma-Specific Outcomes Measures for Children

    May 1, 1998, 00:00

  • PCV15 Study of Procedure Costs And Outcomes Associated with the Pharmacological Treatment of Arterial Disease And Intermittant Claudication in the Department of Claudication in the Department of Defense

    May 1, 1998, 00:00

  • CM2 Clinical Intervention Assessment- Implementation of Default Values for Expediting the Calculation of Cost Savings And Cost Avoidances

    May 1, 1998, 00:00

  • PGD6 A Managed Care Cost Analysis of the Treatment of Psoriasis

    May 1, 1998, 00:00

  • PMH5 The Cost of Treating Schizophrenia in the California Medicaid (MEDI-CAL) Program

    May 1, 1998, 00:00

  • PMH12 Texas Medication Algorithm Project- Feasibility Study of Implementing Medication Algorithms in the Public Mental Health Sector

    May 1, 1998, 00:00

  • PIC4 Cost-Effectiveness of Piperacillin-Tazobactam Versus Ceftazidime in Patients with Febrile Neutropenia

    May 1, 1998, 00:00

  • PMD8 Prenatal Care And Birth Weight in the United States

    May 1, 1998, 00:00

  • MGA2 Disease Management in Hypertension- The Benefits of Meeting Guideline Goals for Blood Pressure

    May 1, 1998, 00:00

  • CVA3 Adherence to Hypertension Therapy- The Effect of Initial Drug Choice

    May 1, 1998, 00:00

  • PHB1 Efficient Strategies for Osteoporosis Testing

    May 1, 1998, 00:00

  • ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma

    May 1, 1998, 00:00

  • CVB2 Development And Cross-Validation of A Comorbidity Index for A Stroke Population

    May 1, 1998, 00:00

  • ID5 Socio-Economic Relevance of Inpatient Treatment of Skin And Soft Tissue Infections with Tazobactam/Piperacillin 0.5 g/2.0 g in Comparison with Amoxicillin/Clavlanic Acid, Ceftriaxone, And Cefotaxime

    May 1, 1998, 00:00

  • PGD5 Predicting Hospitalization of Patients with Diabetes Mellitus- An Application of the Bayesian Discriminant Analysis

    May 1, 1998, 00:00

  • DM1 Interpreting And Using Costeffectiveness Results

    May 1, 1998, 00:00

  • DA6 Strategies for Formulary Comparisons in the Medicaid Managed Care Era

    May 1, 1998, 00:00

  • PHB8 Cost-Effectiveness of Hormone Therapy Versus Calcium Therapy- An Osteoporosis Markov Model

    May 1, 1998, 00:00

  • MM6 Decision Analysis- What is Its Utility for Pharmacoeconomic Analysis?

    May 1, 1998, 00:00

  • PMH1 The Economic Burden of Schizophrenia- Acute General Hospital Costs

    May 1, 1998, 00:00

  • PIC10 The Influence of Case Mix Bias On Costs of Hospitalisation for Lower Respiratory Tract Infection

    May 1, 1998, 00:00

  • PGD7 Consequences of High Hematocrit Maintenance among Hemodialysis Patients

    May 1, 1998, 00:00

  • MHC5 The EuroQol in Parkinsons Disease Research- Rated Current Health vs. Population-Derived Health State Preferences

    May 1, 1998, 00:00

  • PCV8 Readiness to Comply And Outcomes of Antihypertensive Therapy

    May 1, 1998, 00:00

  • CM6 The Use of Patient Self-Reports to Collect Health Care Resource Utilization Data

    May 1, 1998, 00:00

  • MGB5 Adherence of Health Care Workers to Hepatitis B Vaccination (HBV) Policy is Influenced by Leadership

    May 1, 1998, 00:00

  • PCV12 One-Year Clinical And Economic Outcomes of Primary Coronary Angioplasty Using A National Database

    May 1, 1998, 00:00

  • PCV13 Prevalence And Cost of Hospitalizations Due to Angina in the United States Using A National Database

    May 1, 1998, 00:00

  • PCV3 How Does Gender Affect Pharmacotherapy Treatment Decisions for Hypercholesterolemia/Hyperlipidemia?

    May 1, 1998, 00:00

  • PIC11 A Health Economic Evaluation of Paclitaxel And Carboplatin Versus Vinorelbine And Cisplatin Combination Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

    May 1, 1998, 00:00

  • UT1 Trade-Off Preferences for Pharmaceutical Development, Marketing, And Outcomes Evaluation

    May 1, 1998, 00:00

  • MGB4 Relationship Between Quality of Life, Disease Severity, And Physician Visits in Managed Care Patients with Atopic Dermatitis

    May 1, 1998, 00:00

  • UT2 Practical Applications of the Health Utilities Index

    May 1, 1998, 00:00

  • PCV11 The Impact of Unstable Angina on the Use of Medical Resources in Italy

    May 1, 1998, 00:00

  • PMH13 Developing A Task-Based Instrument to Measure Migraine-Related Productivity

    May 1, 1998, 00:00

  • Editorial

    May 1, 1998, 00:00

  • MM1 Monte Carlo Simulation in Health Care Models

    May 1, 1998, 00:00

  • CVB6 Torsemide And Furosemide in the Treatment of the EDEMA of Heart Failure- Interim Results of A Randomized Effectiveness Trial

    May 1, 1998, 00:00

  • GIR2 Noncompliance with Dosing Instructions And Gastrointestinal Outcomes Associated with Alendronate for Osteoporosis in A Large HMO

    May 1, 1998, 00:00

  • PMD3 Use of Administrative Data to Create Disease-Specific Datasets for Use in Health Economic Studies

    May 1, 1998, 00:00

  • GIR6 Predictors of Diagnostic-Related Group Day Outliers in the Medicare End-Stage Renal Disease Population

    May 1, 1998, 00:00

  • PHB6 Health Care Use in Women Age 45 And Older

    May 1, 1998, 00:00

  • PGD10 Bambuterol is A More Cost-Effective Treatment than Salmeterol in Asthma Patients with Nocturnal Symptoms

    May 1, 1998, 00:00

  • MM7 Issues in Developing Economic Models for Managed Care- The Case of Osteoporosis Prevention

    May 1, 1998, 00:00

  • CVB3 Evaluation of the Costs of Coronary Heart Disease in Belgium

    May 1, 1998, 00:00

  • CVB5 Preventing Cardiovascular Disease- Is Primary Prevention with Pravastatin Worth the Money?

    May 1, 1998, 00:00

  • PGD9 Outcomes And Cost-Benefit of Inhaled Corticosteroid Therapy Introduction in Medicaid-Enrolled Asthmatic Children

    May 1, 1998, 00:00

  • GIR4 Prospective Economic Evaluation in A Phase IIIB Renal Transplant Clinical Trial

    May 1, 1998, 00:00
  • «
  • 181 (current)
  • 182